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Key Points 
Question: Can ADHD medications improve performance of higher education 
entrance test for individuals with ADHD? 
Findings: In within-patient analysis, including 930 individuals with ADHD, 
the test scores were significantly higher during medicated periods as 
compared to non-medicated periods. 
Meaning: Treating patients with ADHD medication might help to improve their 
academic performance. 
 
Abstract 
IMPORTANCE  
Individuals with attention-deficit/hyperactivity disorder (ADHD) are at greater 
risk for academic problems. Pharmacologic treatment is effective in reducing 
core symptoms of ADHD, but it is unclear whether it helps to improve 
academic outcomes.  
OBJECTIVE  
To investigate the association of the use of ADHD medication and the 
performance of higher education entrance test in individuals with ADHD. 
DESIGN, SETTING, AND PARTICIPANTS  
This cohort study followed 61,640 individuals with a diagnosis of ADHD from 
January 01, 2006 to December 31, 2013. Using Swedish national registers, 
we extracted records of their pharmacological treatment along with data from 
the Sweden Scholastic Aptitude Test. Using a within-patient design, we 
compared test scores when patients were taking medication for ADHD with 
scores when they were not.  
EXPOSURES 
Periods with and without ADHD medications.  
MAIN OUTCOMES AND MEASURES 
Scores from the higher education entrance examination. 
RESULTS 
Within 930 individuals who had taken multiple tests (2524 tests) and used 
ADHD medications intermittently (mean [SD] age, 22.2 [3.2] years; 493 [53%] 
males), the test scores were on average 4.8 points higher (95% confidence 
interval, 2.26 to 7.34; on the scale of 0-200) during medicated periods as 
compared to non-medicated periods, after adjusting for age and practice 
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effects. Similar associations between ADHD medications and the test scores 
were detected in sensitivity analyses.   
CONCLUSIONS AND RELEVANCE 
Individuals with ADHD scored higher at the higher education entrance tests 
during medicated versus non-medicated periods. This study suggests that 
ADHD medications may help ameliorate educationally relevant outcomes in 
individuals with ADHD.  
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Introduction  
Attention-deficit/hyperactivity disorder (ADHD) is a common psychiatric 
disorder among children and adolescents which can persist to adulthood.1 It 
affects approximately 5-7% of the school-aged population,2-4 and slightly 
under 3% in adults.5-7 On average, individuals with ADHD earn lower school 
grades or standardized test scores, and they receive less schooling, 
compared with peers.8-10 The core symptoms of ADHD, including inattention, 
impulsivity and hyperactivity, may affect school performance; associated 
deficits, such as in attention span and working memory, may exacerbate 
academic difficulties.11,12 
 
Clinical trials have shown that ADHD medications are efficacious in reducing 
the core symptoms of ADHD13 and are generally tolerated in children, 
adolescents and adults,5,14 even though recent Cochrane systematic reviews 
graded these evidence as low quality.15,16 It is, however, less clear whether 
such improvement in behavior translates into better academic outcomes. 
Results from previous studies are mixed, and more importantly, it is difficult to 
evaluate the educational significance of the measured outcomes.17-20  
 
Using information from the Swedish National Registers, we examined the link 
between the use of ADHD medication and a nationally valued academic 
outcome in people who have received a diagnosis of ADHD. We chose a 
within-patient design, in which the same individual's test scores were 
examined when they were on and off medication.   
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Methods 
Patients  
We used the National Patient Register21 to identify a total of 61,640 
individuals with ADHD (code 314 in ICD-9 and F90 in ICD-10) born between 
1976 and 1996. We followed these individuals from January 01, 2006 to 
December 31, 2013. The Migration and Cause of Death Registers were linked, 
using the unique personal identification number, to refine individual follow-up 
periods. The Integrated Database for Labor Market Research and the 
Swedish Military Service Conscription Register were linked to obtain 
information on parents’ highest educational level and the individual’s 
intelligence quotient (IQ) respectively.  
The study was approved by the regional ethics review board in Stockholm, 
Sweden. By Swedish law, there is no requirement for informed consent in 
register based research. 
 
Measures 
Outcome: The outcome was the test score of the Swedish Scholastic Aptitude 
Test (SweSAT; we refer to this henceforth as ‘the test score'). It is an optional 
standardized test,22 which has been an instrument, together with the grade 
point average (GPA) from upper secondary schools in Sweden, for higher 
education selection in Sweden. Applicants to higher education are ranked by 
GPA and/or the test score. There is no restriction on the number of times that 
one may re-take the test; universities automatically consider an applicant’s 
best test score from the re-takes. Therefore, it is common for applicants to 
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take the test multiple times. The SweSAT is usually administered twice a year 
during April and October. Because the level of difficulty varied between tests, 
raw test scores were normed so that scores from different test occasions were 
comparable.23 Since 2011, the test scores are normed to a scale between 
0.00-2.00 (with 0.05 increments). We analyzed the normed test scores on its 
original scale multiplied by 100, yielding test scores ranging between 0-200. 
 
A total of 16 test occasions were included during the follow-up period. We 
extracted test records for the identified individuals with ADHD and excluded 
records of incomplete tests from analyses. Age at testing was restricted to 
between 17 (because students start taking the tests during the second year of 
upper secondary school) and 30 years. For comparison, we extracted the test 
scores for population controls who were not diagnosed with ADHD and were 
matched with each case on sex, birth year, and residential area at the time of 
the first diagnosis, at a ratio of 10:1.  
 
Exposure: The exposure was ADHD medication. We extracted medication 
records of stimulants (including methylphenidate, amphetamine and 
dextroamphetamine) and non-stimulants (atomoxetine) from the Prescribed 
Drug Register. In line with previous definitions,24-26 we defined the medicated 
periods as having two dispensing records with less than 6 months (183 days) 
apart. The non-medicated periods are thus any period other than those 
defined medicated periods during the follow-up. We assigned the test dates to 
the pre-defined medicated/non-medicated periods, to determine the 
medication status at the testing.  
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Covariates: In agreement with previous studies,27,28 we observed significant 
linear and quadratic effects of age and practice (as measured by the number 
of previous tests) in association with the test scores, meaning that test scores 
improve, at a declining rate, as people get older, and as they take more tests. 
This observation forms the basis of the adjustment in the main analyses using 
a within-patient design (the effects of covariates are shown in Supplementary 
Table 1). Other covariates including sex, test year, IQ (measured in Stanine 
scores) and parents’ highest educational level were considered at the cohort 
level (the estimates are shown in Supplementary Table 2). 
  
Statistical analysis 
We first compared the basic characteristics between individuals with ADHD 
who had taken SweSAT test and their matched population controls, as well as 
between ADHD individuals with and without medication during study follow-up 
period. 
 
In the main analyses using the within-patient design, the eligible study 
subjects were individuals with ADHD who had taken repeated tests and used 
ADHD medication during the follow-up. We tested the association between 
medication use and the test scores using a conditional generalized estimation 
equation (CGEE), conditioning on the individual patient.29,30 The analyses 
were performed with and without the adjustment of time-varying confounders 
including age and the number of previous tests. Because each individual 
serves as his or her own control in this design, all the time-invariant 
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confounders were implicitly adjusted for. We also tested the presence of 
carry-over effects to ensure that the estimates were not biased (Online 
Supplement). 
 
For comparison, we also conducted analyses at the cohort level, i.e., without 
controlling for confounding by indication.31,32 In these analyses, the test 
scores from all patients during medicated periods were compared with those 
during non-medicated periods (referred to as ‘between-patient comparison’; 
Online Supplement).  
 
All the analyses were performed in R, using the R package ‘drgee’ for the 
GEE and CGEE models.33  
 
Sensitivity analyses 
To investigate whether the results were sensitive to how the medicated/non-
medicated periods had been defined, we also assigned the medication status 
for each test date according to the number of days since the last dispensing. 
We reasoned that one is more likely to be taking medication if the test date is 
closer to the last dispensing, and conversely, less likely to be on medication if 
there is a large gap in between the last dispensing and the test. The following 
cutoff values were tested: 1) 6 months (183 days) to define both on and off 
medication; 2) 3 months (91 days) to define both on and off medication; 3) on 
medication if the test date was no more than 3 months since the last 
dispensing, and off medication if the last dispensing and the test date was 
more than 6 months apart (those with the gap in between 3 to 6 months were 
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set as missing).  
 
Stimulant ADHD medication might have different efficacy from non-
stimulants.34 To test whether different types of drugs might influence the test 
scores differently, we identified two groups: stimulant-only users, and non-
stimulant/mixed users. The association of medication use and the test scores 
was assessed within these two groups. 
 
ADHD frequently co-occurs with learning disability (LD), but it has been 
shown that attention problems in ADHD patients is not limited to its 
association with LD.35 However, it is not clear whether the association 
between ADHD medication and academic outcomes might differ in patients 
with or without LD. To answer this question, we ran a sensitivity analysis 
restricting our sample to the subset of individuals with ADHD but without co-
existing LD. We identified people with LD either from the National Patient 
Register (code 315 in ICD-9 and F81 in ICD-10) or from the test records 
(there is a special test category for individuals with dyslexia).  
 
In order to evaluate whether the association with test scores was specific to 
ADHD medications, we examined the effect of selective serotonin reuptake 
inhibitors (SSRI) on the test scores within these individuals with ADHD, both 
before and after the adjustment of ADHD medication use. Similar to the case 
of ADHD medications, the dispensing records of SSRI (including fluoxetine, 
citalopram, paroxetine, sertraline, fluvoxamine and escitalopram) were 
extracted from the Prescribed Drug Register and the medicated and non-
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medicated periods of SSRI were defined in the same way.  
 
Results 
Approximately 11% of all 61,640 individuals with ADHD diagnosis had taken 
the test (or 6% if we consider only the tests during the study follow-up). The 
corresponding percentage in the matched population controls was 32% (or 19% 
during follow-up).  
 
Individuals with ADHD who had taken the test took significantly fewer tests at 
a later age as compared to their matched population controls (Table 1). These 
individuals, however, did not differ from matched controls in the mean value of 
the test scores, despite scoring slightly lower in IQ. No difference was 
observed in parents’ highest educational levels between test takers with 
ADHD and matched controls. Of the 3,718 individuals with ADHD who had 
taken the test, 74% (2,745 patients) received ADHD medication (referred to 
as the ‘medicated group’), while the remaining 26% (973 patients) were not 
medicated during the entire follow-up period (referred to as the ‘never-
medicated group’). Notably, the mean value of the test scores was over 10 
points higher among the medicated group than among the never-medicated 
group (94.1 versus 83.5; Table 2).  
  
In the within-patient analysis, we compared the test scores from 930 
individuals with repeated tests (2,524 tests) during their own medicated 
versus non-medicated periods. The use of ADHD medications was associated 
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with an increase of 13.1-point (95% CI, 9.7 to 16.5, P<0.001) in the test 
scores. However, the effect was reduced to a 4.8-point increase (95% CI, 2.3 
to 7.3, P<0.001; Table 3) after accounting for age and practice effects. That is, 
among people who had taken multiple tests and used ADHD medications 
intermittently, the test scores were on average 4.8 points higher (on the scale 
of 0-200; or 0.048 on the original scale) when the patient was on medication. 
The estimated improvement in the test scores appeared to be larger, although 
not significantly different, in males than in females (p-value from testing the 
interaction term of medication status and sex = 0.31; Table 3).  
 
In the between-patient comparison, we did not find a significant association 
between the medication use and the test score (Online Supplement).   
 
Sensitivity analyses 
Within patients, medication was also linked with higher test scores when we 
used alternative definitions of medication status at the test date. The 
estimates of mean difference in the test scores, ranging between 3.6 and 4.0, 
were highly consistent even when we changed the number of days as 
different cut-off values (Table 4). 
 
Seventy-two percent of the medicated ADHD group (665 individuals) were 
stimulant-only users. The association between ADHD stimulants and the test 
scores was weaker than the association with non-stimulant/mixed drugs, 
although the estimates were not significantly different (p-value from testing the 
interaction term of medication status and type of users = 0.23; Table 5). We 
 12 
identified fewer than 100 individuals with ADHD and coexisting LD; this subset 
was too small to warrant separate analyses. Instead we examined the 
association among individuals with ADHD who did not have comorbid LD; the 
estimated mean test score difference was 5.1 points (95% CI, 2.5 to 7.6) in 
this subset.  
 
In contrast, we only found a small, non-statistically-significant, improvement in 
test scores associated with SSRI use, regardless of adjustments for the use of 
ADHD medication. Within individuals with ADHD who had taken SSRI, there 
was a 2.4-point difference (95% CI, -0.9 to 5.6; Table 5) in the mean test 
scores during SSRI-medicated versus non-medicated periods after adjusting 
for the use of ADHD medication. 
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Discussion  
In this study, we examined the performance of individuals with ADHD at the 
higher education entrance examinations during their medicated and non-
medicated periods. Among the people with a diagnosis of ADHD, the use of 
ADHD medication was linked with higher scores in the SweSAT, and that this 
result survived several sensitivity analyses. The size of the effect was 0.048-
point improvement on the original scale of the test scores, equivalent to 0.11 
standard deviation. Comparing the magnitude of effects on test performance, 
the benefit from taking ADHD medication was comparable to having one 
previous test experience (0.12 standard deviation). The effect might be 
stronger for individuals with average or high performance at the initial test 
(Online Supplement). Our results corroborate the emerging evidence from 
randomized clinical trials36-38 and observational studies39-41 that the 
medication is associated with a small improvement in standardised tests or 
GPA,18 and further extend the evidence to the age range of adolescence and 
adulthood which has been particularly understudied.42  
 
This effect size, albeit small, approximates to the increment of 0.05 in the 
normed test scores. Such improvement might translate to a higher rank 
among test applicants, potentially enhancing the chances of receiving higher 
education. The current results, therefore, might have implication on one’s 
educational attainment. In addition, educational level has been shown as a 
strong predictor of occupational outcomes in adult ADHD patients;43 thus, the 
resultant better education might lead to other long-term implications. We note, 
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however, the small effect size suggested that other treatment programs are 
needed to help support individuals with ADHD in educational settings.  
 
In the within-patient design, confounders that are constant within individuals, 
such as genetic make-up for disease severity, intelligence and 
conscientiousness, or family and school environment that stimulate learning 
(e.g., receiving special educational services), are implicitly adjusted for. We 
adjusted for age and practice effects to address the confounding of increased 
test scores at repeated tests due to natural curve of improvement in ADHD 
symptoms44 and improvement in test taking ability. In addition, we did not find 
evidence for exposure-outcome carry-over effects (Online Supplement). This 
suggests that the association between ADHD medication use and the test 
scores after controlling for age and practice effects is relatively robust. 
However, unmeasured confounders that vary within individuals might still be 
present (e.g., periods of time when individuals decide to take medication 
might represent time when they make other health and life decisions that may 
enhance test performance), for which we tested the association of the test 
scores with SSRI, the next commonly used medication in individuals with 
ADHD. No statistically-significant association was detected between SSRI use 
and the test scores, indicating limited impact of such unmeasured factors (a 
further discussion in, Online Supplement). Yet, as in all observational studies 
we are unable to rule out all time-varying confounds. 
 
Compared to many studies that used retrospective parental reports on 
medication use,40 we inferred medication use during the test periods from 
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medication prescription records. Thus, our results were not affected by any 
recall bias. The results, however, rely on whether the medication uses were 
correctly assigned. Using an alternative definition where we traced the test 
date back to the closest drug dispensing and counted the number of days in 
between, we demonstrated that the observed association was not sensitive to 
the definition of medication exposure. But, there is still uncertainty about 
medication status on the test date. Previous studies have shown that ADHD 
treatment non-compliance was found to be the norm rather than the 
exception.19 In the cases where treatment non-compliance occurred during 
our defined medication periods, our estimation was likely to be conservative 
rather than an overestimate of the true medication effect.  
 
Because higher education entrance examinations comparable to the SweSAT 
exist in most countries, our results of a positive association between 
medication use and these tests within individuals with ADHD may generalise 
to some countries with a similar prevalence of ADHD medication use. We 
note the likelihood of some self-selection in our study. First, the proportion of 
individuals who had taken SweSAT tests was nearly three times higher in the 
population controls than in the individuals with ADHD, probably due to a 
higher percentage of school drop-outs45 and of individuals who had chosen 
other educational tracks, such as vocational education and training in the 
ADHD group. Further selection arose from the within-individual design which 
restricted to the individuals who had taken repeated tests. Second, IQ among 
the individuals with ADHD who had taken the tests were comparable to IQ 
among the matched controls, suggesting that our results might be specific to 
 16 
the individuals with normal cognitive function. This might contribute to the 
observation of a similar mean test scores among individuals with ADHD and 
the matched controls, even though we might have expected people with 
ADHD diagnoses to have scored more poorly. We were unable to test 
whether the identified link between ADHD medication and improved test 
performance also applies to individuals with more impaired cognitive function 
or other severe functional impairment. However, it has been suggested that 
the individuals with the greatest deficit are the ones who experience the most 
benefit from ADHD medication.46,47 We, therefore, conjecture that the 
identified link might apply to the full spectrum of functioning in people with 
ADHD. It is important to note, however, by probing the link we explicitly do not 
assume causality. 
 
ADHD medications had almost 50% increase in prescriptions dispensed in the 
US from 2002 to 2010.48 Evidence on links between medication and outcomes 
is an essential part of dispensing decisions. Like all medications, ADHD 
medications have unwanted effects16,49 including concerns regarding non-
serious adverse events, such as decreased appetite and sleep problems, and 
the possibility of serious adverse events,15,50,51 which need to be considered. 
However, this study suggests that ADHD medications may help improve 
performance on an important achievement test and, thus, enhance the 
educational attainment of people with ADHD.  
 
Conclusions: 
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For the people with a diagnosis of ADHD, the use of ADHD medication is 
associated with better performance at the higher education entrance tests. 
This evidence should be considered together with the current list of risks and 
benefits of ADHD medication to guide clinical decisions. 
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Tables 
Table 1. Basic characteristics of individuals with ADHD who had taken 
SweSAT test as compared to their matched population controls. 
 
  
ADHD 
patients 
(n=3718) 
Matched 
controls 
(n=8371)1 
Test of 
group 
differen
ces2 
Average number of tests per person 
(s.d.) 1.58 (1.09) 1.74 (1.20) <0.001 
Mean age at test (s.d.) 22.10 (3.30) 20.55 (2.44) <0.001 
Mean test score (s.d.) 91.40 (46.16) 90.51 (43.02) 0.20 
Mean IQ in stanine scores (s.d.)3 5.62 (1.82) 5.86 (1.74) 0.002 
Father's highest education, over 12 
years of education (%) 44.75% 46.12% 0.17 
Mother's highest education, over 12 
years of education (%) 53.42% 53.19% 0.83 
1. Population controls were matched with each ADHD patient on sex, birth year and 
residential area at the time of diagnosis, at a ratio of 10:1. 8371 individuals from 
37180 matched controls had taken test during the study follow-up.  
2. Two-sided t tests were used for continuous variables. Chi-square tests were used 
for 2-by-2 contingency table, with Yates' correction.  
3. Based on 20% non-missing IQ data in males. 
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Table 2. Basic characteristics of ADHD individuals with and without 
medication during study follow-up period. 
 
  
Medicated 
ADHD group 
(n=2745) 
Never-medicated 
ADHD group 
(n=973) 
Test of 
group 
differences1 
Male (%) 50.49% 56.22% 0.002 
Average number of tests per 
person (s.d.) 1.58 (1.08) 1.53 (0.89) 0.18 
Mean age at test (s.d.) 22.26 (3.36) 21.63 (3.08) <0.001 
Mean test score (s.d.) 94.12 (46.13) 83.46 (45.32) <0.001 
Mean IQ in stanine scores 
(s.d.)2 5.69 (1.86) 5.41 (1.71) 0.08 
Father's highest education, over 
12 years of education (%) 45.69% 42.06% 0.06 
Mother's highest education, 
over 12 years of education (%) 54.92% 49.12% 0.002 
1. Two-sided t tests were used for continuous variables. Chi-square tests were used 
for 2-by-2 contingency table, with Yates' correction.  
2. Based on about 20% non-missing IQ data in males. 
 
  
 20 
 Table 3. Associations between ADHD medication and SweSAT test scores, 
using definition of medicated/non-medicated periods. 
 
  Within-patient comparison1 
  N 
patients 
N tests 
(On/Off)2 
Mean test score 
difference (95% CI)  
P 
Male 493 
1364 
(325/1039) 
5.69 (2.14, 9.23) 0.002 
Female 437 
1160 
(355/805) 
3.60 (0.06, 7.14) 0.05 
Overall 930 
2524 
(680/1844) 
4.80 (2.26, 7.34) <0.001 
 
1. In the within-patient comparison, the test scores during medicated periods were 
compared with non-medicated periods in the same individual, after adjusting for 
both linear and quadratic effects of age and the number of previous tests. The 
analyses were based on individuals with repeated tests.  
2. Total number of tests and the number of tests during medicated versus non-
medicated periods in brackets. All possible combinations of medication use were 
allowed. 
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Table 4. Associations between ADHD medication and SweSAT test scores, 
using days from last dispense to define medication status at test date. 
 
  
6 months as cutoff 
 
3 months as cutoff  
 Less than 3 months as 
ON, more than 6 months 
as OFF 
 Estimate (95% CI) P  Estimate (95% CI) P  Estimate (95% CI) P 
Male 4.80 (1.61, 7.98) 0.003 4.05 (0.90, 7.19) 0.01 4.83 (1.28, 8.39) 0.007 
Female 2.46 (-1.41, 6.33) 0.21  2.95 (-0.30, 6.21) 0.08  3.00 (-1.06, 7.05) 0.15 
Overall 3.72 (1.26, 6.19) 0.003  3.56 (1.28, 5.84) 0.002  4.02 (1.34, 6.69) 0.003 
Estimates of medication effect (i.e., estimated mean difference in the test scores 
while one was on medication versus off medication) were from within-patient analysis, 
adjusted for both linear and quadratic effects of age and the number of previous tests. 
The number of patients and tests were the same as in Table 3 (within-patient level).  
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Table 5. Associations between ADHD medication and SweSAT test scores, in 
sensitivity analyses. 
 
Types of cohort, medication N N tests 
Mean test score 
difference 
(95% CI) 
P 
ADHD diagnosed in the National 
Patient Register 
    
Within stimulant-only users 665 1816 3.81 (0.94, 6.69) 0.009 
Within non-stimulant/mixed users 265 708 6.93 (1.81, 12.05) 0.008 
Within patients without co-existing LD 844 2264 5.05 (2.47, 7.62) <0.001 
SSRI use and test scores  
(not adjusted for ADHD medication) 
556 1475 2.71 (-0.57, 5.99) 0.11 
SSRI use and test scores  
(adjusted for ADHD medication) 445 1207 2.37 (-0.88, 5.63) 0.15 
Estimates of medication effect (i.e., estimated mean difference in the test scores 
during medicated periods compared to non-medicated periods) were from within-
patient analysis, adjusting for both linear and quadratic effects of age and the number 
of previous tests.   
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Testing carry-over effect: 
 
The within-patient design assumes that there is no carry-over effect between 
exposures and outcomes for the same individual.1 Carry-over effects, in this context, 
can take place in many forms, with some more plausible than others: for example, 
medication use at an earlier test can influence the decision of medication use 
(“exposure-to-exposure”), or more directly influence the scores (“exposure-to-
outcome”), at the following test(s); or, an individual's scores at earlier tests can 
influence his or her scores (“outcome-to-outcome”) or medication use (“outcome-to-
exposure”) at later test(s). Except for the first form (i.e., earlier medication use 
influence later use), these carry-over effects, if exist but are not accounted for, will 
lead to bias in the estimates from these models.1 Therefore, we adjusted for the age 
and practice effects, both linear and quadratic terms, to account for the outcome-to-
outcome carry-over. In addition, we tested the presence of the other two forms of 
carry-over, by fitting the specific paths into the model. To test whether the exposure-
to-outcome carry-over exists, we examined the association of current test scores with 
the medication use at earlier tests, while adjusting for an indicator of the first test 
(because no information on the prior medication use), current medication use, as well 
as the age and practice effects. Similarly, to test whether the outcome-to-exposure 
carry-over exist, we examined the association of current medication use with 
previous test scores, while adjusting for an indicator of first test, current test scores, 
as well as age and practice effects.  
 
There was no evidence suggesting that the exposure-outcome carry-over effects 
exist. The effect of previous medication use on the current test score was not 
significantly different from 0 (-0.74 to 4.03), neither was the odds ratio of previous 
test score on the use of current medication different from 1 (0.99 to 1.03). These 
results suggest that the association between ADHD medication and test scores after 
controlling for the learning effect is not biased by other types of carry-over effects.   
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Between-patient comparison: 
For comparison with results from the within-individual analysis, we also conducted 
analyses at the cohort level, i.e., the test scores from all patients during medicated 
periods were compared with those during non-medicated periods (referred to as 
‘between-patient comparison’); thus there was no restriction on study subjects. We 
used generalized estimation equation models to examine the associations between 
the use of ADHD medication and the test scores from all patients, with robust 
standard errors accounting for the correlated test scores from the same patients. The 
between-patient comparison was adjusted for age, sex, number of previous tests, 
test year, parental education level and IQ. 
 
In the between-patient comparison when confounding by indication was not 
controlled for, we did not find a significant association between the medication use 
and the test score. For all individuals in the medicated ADHD group, the estimated 
mean difference in the test scores was 1.2 (95% CI, -2.4 to 4.8) comparing all 
medicated periods with non-medicated periods.   
 
 
  Between-patient comparison1 
  
N patients 
N tests 
(On/Off)2 
Mean test score difference 
(95% CI) 
P 
Male 1386 
2257 
(570/1687) 
-0.63 (-5.56, 4.30) 0.80 
Female 1359 
2082 
(602/1480) 
2.67 (-2.55, 7.90) 0.32 
Overall 2745 
4339 
(1172/3167) 
1.23 (-2.38, 4.83)3 0.51 
 
1. In the between-patient comparison, the test scores from all individuals during medicated 
periods were compared with those during non-medicated periods, after adjusting for both 
linear and quadratic effects of age and the number of previous tests, test year, parents' 
highest education level (whether or not had over 12 years of education), and sex in the 
overall analysis. The presented results were not adjusted for IQ due to large percentage 
of missing data. 
2. Total number of tests and the number of tests during medicated versus non-medicated 
periods in brackets. All possible combinations of medication use were allowed. 
3. The mean test score difference in the between-patient comparison was -1.02, 95% CI was 
-9.29 to 7.24 after adjusting for IQ.  
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The concomitant use of SSRI: 
The concomitant use of SSRI appeared to be more prevalent during ADHD 
medicated periods compared to non-medicated periods (see the table below). We 
note that the non-significant improvement in test scores associated with SSRI, 
approximately 0.06 standard deviation of the test scores, was less likely to indicate a 
general effect related to medication pattern; instead, it was perhaps driven by the 
subset of individuals with ADHD and coexisting depression (within individuals with 
both ADHD and depression who had taken repeated tests, the estimated mean 
difference in the test scores due to SSRI was twice as large as the estimate from 
individuals with ADHD only, after adjusting for ADHD medication use; results not 
shown). This observation reflects previous findings that SSRI use is associated with 
improving attention and remaining executive function in patients with depression.2  
 
 ADHD medication periods 
 1844 OFF periods 680 ON periods 
Intermittent use of SSRI; number (%) 
OFF 734 (39.8%) 250 (36.8%) 
ON 142 (7.7%) 81 (11.9%) 
Never-treated 968 (52.5%) 349 (51.3%) 
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Stratifying subjects by test performance: 
In this sensitivity analysis, we aimed to test whether the association between ADHD 
medication and test scores differed among individuals with different test performance. 
We indirectly investigated this question by ranking subjects according to the scores 
from their first tests: those within the bottom 20% were considered as ‘low’ 
performance group, within top 20% were considered as ‘high’ performance group and 
the remaining ones were ‘average’ performance group. It should be noted that this 
represents a crude way of stratifying subjects, because scores at different test 
occasions which might have a varying level of difficulties were pooled together. We 
then performed within-individual analyses in each of these three groups. The results 
are shown below: 
 
 N 
individuals 
N 
tests 
Mean test score 
difference (95% CI) 
P 
Low performance 
group (scores from 
the first test below 50) 
192 512 0.36 (-5.06, 5.78) 0.90 
Average performance 
group (scores from 
the first test between 
50 to 130) 
555 1501 5.67 (2.69, 8.65) 0.0002 
High performance 
group (scores from 
the first test above 
130) 
183 511 7.80 (2.32, 13.27) 0.005 
 
 
There was no evidence for a medication effect among the low performance group. 
The medication effect appeared to be the strongest in the high performance group, 
but its wide confidence interval (CI) completely overlapped with the CI from the 
average performance group.   
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Supplementary Table 1. The effect of adjustments at the within-patient 
comparison.  
 
Variables Effect S.E. P-value 
Age 15.49 3.36 4E-06 
age2 -0.28 0.07 8E-05 
previous number of tests 5.86 0.73 1E-15 
previous number of tests2 -0.19 0.11 8E-02 
  
 
 
 
Supplementary Table 2. The effect of adjustments at the between-patient 
comparison.  
 
Variables Effect S.E. P-value 
Age -5.93 3.46 0.087 
age2 0.17 0.07 0.022 
previous number of 
tests 
13.77 1.23 < 2e-16 
previous number of 
tests2 
-0.87 0.22 6E-05 
test year 2007 -5.64 3.05 0.0641 
test year 2008 -8.43 3.45 0.0145 
test year 2009 -9.46 3.23 0.0034 
test year 2010 -11.51 3.26 0.0004 
test year 2011 -12.59 3.24 0.0001 
test year 2012 -14.91 3.16 2E-06 
test year 2013 -18.35 3.15 6E-09 
sex_female -13.08 1.80 4E-13 
Father's highest 
education; over 12 
years of education 
12.58 1.92 6E-11 
Mother's highest 
education; over 12 
years of education 
14.32 1.97 4E-13 
* IQ had an effect of 12.05 (s.e.=2.27, P=1e-7; and the effect of mother's highest 
education was reduced to 2.77, s.e.=5.80, P=0.63) in the adjusted model that was 
based on 20% non-missing data in males. 
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